{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:48:02Z","timestamp":1792799282332,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11914-025-00905-6","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T11:49:01Z","timestamp":1740224941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1\u201384 and Palopegteriparatide"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-3381","authenticated-orcid":false,"given":"Anda Mihaela","family":"Naciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-2245","authenticated-orcid":false,"given":"Yu Kwang Tay","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0700","authenticated-orcid":false,"given":"Gaia","family":"Tabacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3657-2070","authenticated-orcid":false,"given":"Guido","family":"Zavatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"issue":"2","key":"905_CR1","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1530\/EJE-21-1044","volume":"186","author":"J Bollerslev","year":"2022","unstructured":"Bollerslev J, et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders. Eur J Endocrinol. 2022;186(2):R33\u201363. https:\/\/doi.org\/10.1530\/EJE-21-1044.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"905_CR2","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1002\/jbmr.4716","volume":"37","author":"AA Khan","year":"2022","unstructured":"Khan AA, et al. Management of hypoparathyroidism. J Bone Miner Res. 2022;37(12):2663\u201377. https:\/\/doi.org\/10.1002\/jbmr.4716.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"905_CR3","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1002\/JBMR.4698","volume":"37","author":"S Van Uum","year":"2022","unstructured":"Van Uum S, et al. Initial Assessment and monitoring of patients with chronic hypoparathyroidism: a systematic current practice survey. J Bone Miner Res. 2022;37(12):2630\u201341. https:\/\/doi.org\/10.1002\/JBMR.4698.","journal-title":"J Bone Miner Res"},{"key":"905_CR4","doi-asserted-by":"publisher","unstructured":"Mannstadt M et al. \u201cHypoparathyroidism,\u201d Nat Rev Dis Primers. 2017;3 https:\/\/doi.org\/10.1038\/NRDP.2017.55.","DOI":"10.1038\/NRDP.2017.55"},{"issue":"1","key":"905_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1210\/JC.2017-01555","volume":"103","author":"A Palermo","year":"2018","unstructured":"Palermo A, et al. PTH(1\u201334) for Surgical Hypoparathyroidism: A 2-year prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab. 2018;103(1):271\u201380. https:\/\/doi.org\/10.1210\/JC.2017-01555.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"905_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"Mannstadt M, et al. Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1(4):275\u201383. https:\/\/doi.org\/10.1016\/S2213-8587(13)70106-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"905_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3803\/ENM.2024.1916","volume":"39","author":"L Rejnmark","year":"2024","unstructured":"Rejnmark L. Treatment of hypoparathyroidism by re-establishing the effects of parathyroid hormone. Endocrinol Metab. 2024;39(2):262\u20136. https:\/\/doi.org\/10.3803\/ENM.2024.1916.","journal-title":"Endocrinol Metab"},{"key":"905_CR8","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGAE693","author":"BL Clarke","year":"2024","unstructured":"Clarke BL, et al. Efficacy and Safety of TransCon PTH in Adults with Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2024. https:\/\/doi.org\/10.1210\/CLINEM\/DGAE693.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"905_CR9","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1007\/S12325-024-02843-8","volume":"41","author":"L Rejnmark","year":"2024","unstructured":"Rejnmark L, et al. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024;41(6):2500\u201318. https:\/\/doi.org\/10.1007\/S12325-024-02843-8.","journal-title":"Adv Ther"},{"issue":"1","key":"905_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/JBMR.4726","volume":"38","author":"AA Khan","year":"2023","unstructured":"Khan AA, et al. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023;38(1):14\u201325. https:\/\/doi.org\/10.1002\/JBMR.4726.","journal-title":"J Bone Miner Res"},{"key":"905_CR11","doi-asserted-by":"publisher","unstructured":"Clarke BL, Kay Berg J, Fox J, Cyran JA, Lagast H. \u201cPharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1\u201384) in patients with hypoparathyroidism: an open-label, single-dose, phase I study,\u201d Clin Ther.\u00a02014;36(5):722\u2013736 https:\/\/doi.org\/10.1016\/J.CLINTHERA.2014.04.001.","DOI":"10.1016\/J.CLINTHERA.2014.04.001"},{"issue":"10","key":"905_CR12","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/JBMR.1964","volume":"28","author":"T Sikjaer","year":"2013","unstructured":"Sikjaer T, Amstrup AK, Rolighed L, Kjaer SG, Mosekilde L, Rejnmark L. PTH(1\u201384) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res. 2013;28(10):2232\u201343. https:\/\/doi.org\/10.1002\/JBMR.1964.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"905_CR13","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1210\/JC.2012-1808","volume":"97","author":"DM Mitchell","year":"2012","unstructured":"Mitchell DM, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507\u201314. https:\/\/doi.org\/10.1210\/JC.2012-1808.","journal-title":"J Clin Endocrinol Metab"},{"key":"905_CR14","unstructured":"\u201c(Abstract MO0173). 33rd Annual Meeting of the American Society of Bone and Mineral Research. Vol 26(Suppl 1). San Diego, CA: J Bone Miner Res. 2011\u201d"},{"issue":"1","key":"905_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/S12020-016-1141-0","volume":"55","author":"BL Clarke","year":"2017","unstructured":"Clarke BL, Vokes TJ, Bilezikian JP, Shoback DM, Lagast H, Mannstadt M. Effects of parathyroid hormone rhPTH(1\u201384) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine. 2017;55(1):273\u201382. https:\/\/doi.org\/10.1007\/S12020-016-1141-0.","journal-title":"Endocrine"},{"issue":"11","key":"905_CR16","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1210\/JC.2019-01010","volume":"104","author":"M Mannstadt","year":"2019","unstructured":"Mannstadt M, et al. Safety and efficacy of 5 years of treatment With recombinant human parathyroid hormone in adults with hypoparathyroidism. J Clin Endocrinol Metab. 2019;104(11):5136\u201347. https:\/\/doi.org\/10.1210\/JC.2019-01010.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"905_CR17","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1210\/JC.2019-00893","volume":"104","author":"YKD Tay","year":"2019","unstructured":"Tay YKD, et al. Therapy of hypoparathyroidism with rhpth(1\u201384): a prospective, 8-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2019;104(11):5601\u201310. https:\/\/doi.org\/10.1210\/JC.2019-00893.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"905_CR18","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/JBMR.470","volume":"26","author":"T Sikjaer","year":"2011","unstructured":"Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L. The effect of adding PTH(1\u201384) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26(10):2358\u201370. https:\/\/doi.org\/10.1002\/JBMR.470.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"905_CR19","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1210\/JC.2013-1239","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, et al. The effect of PTH(1\u201384) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab. 2013;98(6):2356\u201361. https:\/\/doi.org\/10.1210\/JC.2013-1239.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"905_CR20","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1210\/JC.2018-02430","volume":"104","author":"G Tabacco","year":"2019","unstructured":"Tabacco G, et al. Quality of life in hypoparathyroidism improves with rhPTH(1\u201384) throughout 8 years of therapy. J Clin Endocrinol Metab. 2019;104(7):2748\u201356. https:\/\/doi.org\/10.1210\/JC.2018-02430.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"905_CR21","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1210\/JC.2014-2267","volume":"99","author":"NE Cusano","year":"2014","unstructured":"Cusano NE, et al. PTH(1\u201384) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab. 2014;99(10):3694\u20139. https:\/\/doi.org\/10.1210\/JC.2014-2267.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"905_CR22","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/S00198-014-2677-6","volume":"25","author":"T Sikjaer","year":"2014","unstructured":"Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH(1\u201384) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014;25(6):1717\u201326. https:\/\/doi.org\/10.1007\/S00198-014-2677-6.","journal-title":"Osteoporos Int"},{"issue":"2","key":"905_CR23","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1210\/JC.2017-01471","volume":"103","author":"TJ Vokes","year":"2018","unstructured":"Vokes TJ, et al. Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J Clin Endocrinol Metab. 2018;103(2):722\u201331. https:\/\/doi.org\/10.1210\/JC.2017-01471.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"905_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.23736\/S2724-6507.21.03527-2","volume":"46","author":"YKD Tay","year":"2021","unstructured":"Tay YKD, Tabacco G, Bilezikian JP. Bone quality in hypoparathyroidism. Minerva Endocrinol. 2021;46(3):325\u201334. https:\/\/doi.org\/10.23736\/S2724-6507.21.03527-2.","journal-title":"Minerva Endocrinol"},{"issue":"1","key":"905_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1210\/JC.2012-2984","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, et al. Therapy of hypoparathyroidism with PTH(1\u201384): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98(1):137\u201344. https:\/\/doi.org\/10.1210\/JC.2012-2984.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"905_CR26","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1210\/JC.2015-4135","volume":"101","author":"MR Rubin","year":"2016","unstructured":"Rubin MR, et al. Therapy of hypoparathyroidism With PTH(1\u201384): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab. 2016;101(7):2742\u201350. https:\/\/doi.org\/10.1210\/JC.2015-4135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"905_CR27","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/JBMR.3543","volume":"33","author":"MR Rubin","year":"2018","unstructured":"Rubin MR, et al. The effects of long-term administration of rhPTH(1\u201384) in hypoparathyroidism by bone histomorphometry. J Bone Miner Res. 2018;33(11):1931\u20139. https:\/\/doi.org\/10.1002\/JBMR.3543.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"905_CR28","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/JBMR.4005","volume":"35","author":"NE Cusano","year":"2020","unstructured":"Cusano NE, et al. Changes in skeletal microstructure through four continuous years of rhPTH(1\u201384) therapy in hypoparathyroidism. J Bone Miner Res. 2020;35(7):1274\u201381. https:\/\/doi.org\/10.1002\/JBMR.4005.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"905_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/JBMR.4780","volume":"38","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, et al. The clinical and skeletal effects of long-term therapy of hypoparathyroidism with rhPTH(1\u201384). J Bone Miner Res. 2023;38(4):480\u201392. https:\/\/doi.org\/10.1002\/JBMR.4780.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"905_CR30","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/JBMR.4016","volume":"35","author":"DB Karpf","year":"2020","unstructured":"Karpf DB, et al. A randomized double-blind placebo-controlled first-in-human phase 1 trial of transcon pth in healthy adults. J Bone Miner Res. 2020;35(8):1430\u201340. https:\/\/doi.org\/10.1002\/JBMR.4016.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"905_CR31","doi-asserted-by":"publisher","first-page":"E372","DOI":"10.1210\/CLINEM\/DGAB577","volume":"107","author":"AA Khan","year":"2022","unstructured":"Khan AA, et al. PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of transcon pth in adult hypoparathyroidism. J Clin Endocrinol Metab. 2022;107(1):E372\u201385. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB577.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"905_CR32","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1210\/jcem.83.10.5185","volume":"83","author":"KK Winer","year":"1998","unstructured":"Winer KK, Yanovski JA, Sarani B, Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1\u201334 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998;83(10):3480\u20136. https:\/\/doi.org\/10.1210\/jcem.83.10.5185.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"905_CR33","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1210\/JC.2007-2552","volume":"93","author":"KK Winer","year":"2008","unstructured":"Winer KK, Sinaii N, Peterson D, Sainz B, Cutler GB. Effects of once versus twice-daily parathyroid hormone 1\u201334 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab. 2008;93(9):3389\u201395. https:\/\/doi.org\/10.1210\/JC.2007-2552.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"905_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","volume":"276","author":"KK Winer","year":"1996","unstructured":"Winer KK. Synthetic human parathyroid hormone 1\u201334 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996;276(8):631. https:\/\/doi.org\/10.1001\/jama.1996.03540080053029.","journal-title":"JAMA"},{"issue":"6","key":"905_CR35","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1210\/CLINEM\/DGAA113","volume":"105","author":"JP Bilezikia","year":"2020","unstructured":"Bilezikia JP. Hypoparathyroidism. J Clin Endocrinol Metab. 2020;105(6):1722\u201301736. https:\/\/doi.org\/10.1210\/CLINEM\/DGAA113.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"905_CR36","doi-asserted-by":"publisher","first-page":"R229","DOI":"10.1530\/EC-20-0366","volume":"9","author":"G Zavatta","year":"2020","unstructured":"Zavatta G, Clarke BL. Challenges in the management of chronic hypoparathyroidism. Endocr Connect. 2020;9(10):R229\u201340. https:\/\/doi.org\/10.1530\/EC-20-0366.","journal-title":"Endocr Connect"},{"issue":"3","key":"905_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eprac.2023.12.001","volume":"30","author":"MR Rubin","year":"2024","unstructured":"Rubin MR, Cusano N, Yin S, Tokareva E, Ayodele O, Finkelman RD. Extended treatment with recombinant human parathyroid hormone (1\u201384) in adult patients with chronic hypoparathyroidism. Endocr Pract. 2024;30(3):200\u20138. https:\/\/doi.org\/10.1016\/j.eprac.2023.12.001.","journal-title":"Endocr Pract"},{"issue":"1","key":"905_CR38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/S12020-024-03807-2","volume":"85","author":"M B\u00fcttner","year":"2024","unstructured":"B\u00fcttner M, Singer S, Taylor K. Quality of life in patients with hypoparathyroidism receiving standard treatment: an updated systematic review. Endocrine. 2024;85(1):80\u201390. https:\/\/doi.org\/10.1007\/S12020-024-03807-2.","journal-title":"Endocrine"},{"key":"905_CR39","doi-asserted-by":"publisher","unstructured":"Sikjaer T, Eskildsen SF, Underbjerg L, \u00d8stergaard L, Rejnmark L, Evald L. \u201cHypoparathyroidism: changes in brain structure, cognitive impairment, and reduced quality of life,\u201d J Bone Mineral Res. 2024; pp. 1\u201312, 2024, https:\/\/doi.org\/10.1093\/jbmr\/zjae063.","DOI":"10.1093\/jbmr\/zjae063"},{"issue":"12","key":"905_CR40","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1002\/JBMR.4676","volume":"37","author":"L Yao","year":"2022","unstructured":"Yao L, et al. Parathyroid hormone therapy for managing chronic hypoparathyroidism: a systematic review and meta-analysis. J Bone Miner Res. 2022;37(12):2654\u201362. https:\/\/doi.org\/10.1002\/JBMR.4676.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"905_CR41","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/JBMR.4566","volume":"37","author":"G Puliani","year":"2022","unstructured":"Puliani G, et al. Safety and efficacy of PTH 1\u201334 and 1\u201384 therapy in chronic hypoparathyroidism: a meta-analysis of prospective trials. J Bone Miner Res. 2022;37(7):1233\u201350. https:\/\/doi.org\/10.1002\/JBMR.4566.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"905_CR42","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1210\/jc.2017-02593","volume":"103","author":"KK Winer","year":"2018","unstructured":"Winer KK. Does PTH replacement therapy improve quality of life in patients with chronic hypoparathyroidism? J Clin Endocrinol Metab. 2018;103(7):2752\u20135. https:\/\/doi.org\/10.1210\/jc.2017-02593.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"905_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/CLINEM\/DGAA490","volume":"105","author":"KS Chen","year":"2020","unstructured":"Chen KS, et al. Five-year estimated glomerular filtration rate in patients with hypoparathyroidism treated with and without rhPTH(1\u201384). J Clin Endocrinol Metab. 2020;105(10):1\u20139. https:\/\/doi.org\/10.1210\/CLINEM\/DGAA490.","journal-title":"J Clin Endocrinol Metab"},{"key":"905_CR44","doi-asserted-by":"publisher","unstructured":"Liao EP, Cusano NE. Use of rhPTH (1-84) for hypoparathyroidism during early pregnancy and lactation. Endocrinol, Diabetes Metab Case Rep. 2023;2023(2). https:\/\/doi.org\/10.1530\/EDM-22-0401.","DOI":"10.1530\/EDM-22-0401"}],"updated-by":[{"DOI":"10.1007\/s11914-025-00916-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000}}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-025-00905-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-025-00905-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-025-00905-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:11:02Z","timestamp":1768471862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-025-00905-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s11914-025-00905-6","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"12 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the original version of this article, the FDA and EMA label indications for palopegteriparatide and rhPTH(1-84) were inadvertently exchanged in Table 1. The table has been corrected. The Authors sincerely apologize for this error.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11914-025-00916-3","URL":"https:\/\/doi.org\/10.1007\/s11914-025-00916-3","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Statements and Declarations: AP: advisory board for Ascendis Pharma; speakers bureau for Ascendis Pharma. GZ: advisory board for Ascendis Pharma; speakers bureau for Ascendis Pharma. AMN, YKD AND GT have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12"}}